Suchergebnisse - "Tondini, Carlo"

PubPharm (10)

1

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer : Final analysis of MetaPHER, a phase IIIb single-arm safety study

enthalten in: Breast cancer research and treatment | 2021

von Kuemmel, S. | Tondini, C. | Abraham, J. | +13

2

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

enthalten in: Breast cancer research and treatment | 2021

von Kuemmel, S. | Tondini, C. | Abraham, J. | +13

3

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

enthalten in: Breast cancer research and treatment | 2021

von Kuemmel, S. | Tondini, C. | Abraham, J. | +13

4

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

enthalten in: Breast cancer research and treatment | 2021

von Kuemmel, S. | Tondini, C. | Abraham, J. | +13

5

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

enthalten in: Breast cancer research : BCR | 2019

von Rossi, L. | Biagioni, C. | McCartney, A. | +17

6

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

enthalten in: Breast cancer research | 2019

von Rossi, L. | Biagioni, C. | McCartney, A. | +17

7

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

enthalten in: Breast cancer research | 2019

von Rossi, L. | Biagioni, C. | McCartney, A. | +17

8

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

enthalten in: Breast cancer research and treatment | 2012

von Pestrin, M. | Bessi, S. | Puglisi, F. | +13

9

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

enthalten in: Breast cancer research and treatment | 2012

von Pestrin, M. | Bessi, S. | Puglisi, F. | +13

10

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

enthalten in: Breast cancer research and treatment | 2012

von Pestrin, M. | Bessi, S. | Puglisi, F. | +13

1
[1]